Nice webcast despite NOT addressing some of our previous inquries such as how compounds/disease indications are split between RVX/Zenith, status of autoimmune program, or status of other pre-clinical molecules such as RVX297. Nothing new on the licensing deal, partnering or animal health indication opportunities either.

What we did learn is that the closing date for the re-organization will be July 31, 2016 (or August 1 perhaps). There are currently 125.2 MM shares (with estimated value of $1/share), so at the time of the split those who own Zenith will own proportional amounts of Zenith Capital Corp and Zenith Epigenetics Ltd. No mention of reverse takeover listing on TSX anymore, but instead are looking at IPO on the Nasdaq when market conditions are right.

As for the prostate cancer trial, they should finish enrolling their first cohort by next week and will have PK/Safety data in Fall 2016. There was a very good slide on how the dose escalation portion of the slide works in determining the maximum tolerated dose. All sites but UCLA are activated, and UCLA is anticipated to be activated very soon. They will expand to combination therapies in H2 2016. They expect to reach proof of concept H1 2017, which seems much later than the initial estimates (or maybe we had a misconception about this?).

Only 1 person during the Q&A and it was George Zavoico. During one of his questions, Don answered that what differentiates Zenith's pan-inhibitor is that it is more selective to BRD4 than the other bromodomain proteins. I need to re-listen to the Q&A part again...I think there was some mention of planning to present the PK/safety data at a Fall meeting, but I didn't catch much of this. Anyone else here this part?

BearDownAZ